AZSTARYS® is available nationwide
Primary end point: LS mean change from baseline
in SKAMP-C scores averaged over 13 hours1,2,a,b
The efficacy of AZSTARYS® (serdexmethylphenidate and dexmethylphenidate) was evaluated in a multicenter, dose-optimized, randomized, double-blind, placebo-controlled, parallel-group, analog classroom study of 150 children (aged 6 - 12 years) with ADHD.1,2
aSKAMP is a 13-item assessment of classroom behaviors in children with ADHD, including attention, deportment, quality of work, and compliance.
bPredose Visit 5 as baseline. Baseline score was 17.9 for both groups.
cDifference (active drug minus placebo) in LS mean change from baseline.
Key secondary end point: mean change from baseline in
SKAMP-C scores at each time point1
Onset of effect was defined as the first time point showing a statistically significant difference vs placebo. Duration of effect was defined as the length of time between the first and last time points showing statistical significance vs placebo, or the last measured time point.2,a,b
aSKAMP is a 13-item assessment of classroom behaviors in children with ADHD, including attention, deportment, quality of work, and compliance.2
d-MPH, dexmethylphenidate; LS, least squares; PERMP, Permanent Product Measure of Performance; PERMP-A, Permanent Product Measure of Performance-Attempted; PERMP-C, Permanent Product Measure of Performance-Correct; SKAMP, Swanson, Kotkin, Agler, M-Flynn, and Pelham; SKAMP-C, Swanson, Kotkin, Agler, M-Flynn, and Pelham-Combined; WREMB-R, Weekly Rating of Evening and Morning Behavior-Revised.
References: 1. AZSTARYS. Prescribing information. Corium Inc; 2021. 2. Kollins SH, Braeckman R, Guenther S, et al. A randomized, controlled laboratory classroom study of serdexmethylphenidate and d-methylphenidate capsules in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2021;31(9):597-609. doi:10.1089/cap.2021.0077 3. Data on file. Corium, Inc. 4. Wehmeier PM, Dittmann RW, Schacht A, Helsberg K, Lehmkuhl G. Morning and evening behavior in children and adolescents treated with atomoxetine once daily for attention-deficit/hyperactivity disorder (ADHD): findings from two 24-week, openlabel studies. Child Adolesc Psychiatry Ment Health. 2009;3(1):5. doi:10.1186/1753-2000-3-5
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder
(ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE
Please click here for Full
Prescribing Information,
including Boxed WARNING.
AZSTARYS is a central nervous system
(CNS) stimulant indicated for the
treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in
patients 6 years and older.
WARNING: ABUSE AND DEPENDENCE
The site you're about to enter is intended for US healthcare professionals only.
By selecting OK to continue, you confirm you are a healthcare professional.